Stockholders’ Equity (Details Narrative) - USD ($) |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Apr. 28, 2026 |
Apr. 24, 2026 |
Sep. 30, 2026 |
Jun. 30, 2026 |
Sep. 30, 2026 |
Sep. 30, 2025 |
|
| Subsidiary, Sale of Stock [Line Items] | ||||||
| Stock issued new shares | $ 312,000 | $ 55,000 | ||||
| Proceeds from sale of stock, net | $ 3,848,000 | $ 0 | ||||
| Underwriting Agreement [Member] | ||||||
| Subsidiary, Sale of Stock [Line Items] | ||||||
| Proceeds from sale of stock, net | 3,481,000 | |||||
| Description of underwriting agreement | On April 24, 2026, the Company entered into an Underwriting Agreement with Dawson James Securities, Inc. (the “Underwriter”). Pursuant to the terms of the Underwriting Agreement, the Company agreed to issue and sell to the Underwriter an aggregate of 2,962,963 units, each unit consisting of one share of common stock, par value $0.0001 per share or, in lieu of common stock, if purchasing common stock would result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% of the outstanding common stock, a pre-funded warrant, together with one warrant to purchase one share of common stock at an exercise price equal to $1.35 per share, in a public offering. The public offering price for each unit was $1.35. | |||||
| Additional shares | 444,444 | |||||
| Warrant purchase | 444,444 | |||||
| Shares of common stock | 444,444 | |||||
| Stock issuance costs | $ 75,000 | |||||
| Proceeds from sale of stock, gross | $ 4,000,000 | |||||
| Underwriting Agreement [Member] | Pre-Funded Warrants [Member] | ||||||
| Subsidiary, Sale of Stock [Line Items] | ||||||
| Warrant purchase | 1,312,247 | |||||
| Underwriting Agreement [Member] | Warrant [Member] | ||||||
| Subsidiary, Sale of Stock [Line Items] | ||||||
| Warrant purchase | 3,407,404 | |||||
| Exercise price | $ 1.35 | |||||
| Proceeds from sale of stock, gross | $ 3,481,000 | |||||
| Underwriting Agreement [Member] | Common Stock [Member] | ||||||
| Subsidiary, Sale of Stock [Line Items] | ||||||
| Stock issued new, shares | 1,650,716 | |||||
| Underwriting Agreement [Member] | Common Stock [Member] | Pre-Funded Warrants [Member] | ||||||
| Subsidiary, Sale of Stock [Line Items] | ||||||
| Warrant purchase | 1,312,247 | |||||
| Underwriting Agreement [Member] | Common Stock [Member] | Warrant [Member] | ||||||
| Subsidiary, Sale of Stock [Line Items] | ||||||
| Warrant purchase | 3,407,404 | |||||
| At-the-Market Sale [Member] | ||||||
| Subsidiary, Sale of Stock [Line Items] | ||||||
| Stock issued new, shares | 289,303 | |||||
| Stock issued new shares | $ 405,000 | |||||
| Proceeds from sale of stock, net | $ 367,000 | |||||
| X | ||||||||||
- Definition Exercise price per share or per unit of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Aggregate number of common shares reserved for future issuance. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The cash outflow for cost incurred directly with the issuance of an equity security. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash inflow from the additional capital contribution to the entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of additional shares authorized for issuance under share-based payment arrangement. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Disclose the effect on the financial statements of underwriting commitments open at year-end and subsequently settled. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|